Solent™ Oral

The foundation of SOLENT™ (SOLubility ENhancement Technology) lies in its utilisation of a specially designed formulation matrix incorporating a wide variety of commercially available, liquid-based GRAS excipients approved for both preclinical and clinical use.

Using as little as 50-100 mg of API in total and 50 µl excipient/s per hit, we screen rapidly up to 128 formulations in parallel at high dosage levels (up to 100 mg/ml), with the highest priority being to solubilise your poorly soluble compound and keep it in solution until oral absorption can take place.
 

Benefits of the SOLENT™ Oral screening platform include:

• Unlike other commercially available screens, all excipients have GRAS status, ensuring all formulations identified can be used for both preclinical and clinical use at the required dosage level
• Excipients chosen based on safety profile in model used (e.g. rat, mouse, dog etc)
• Up to 128 formulation compositions assessed simultaneously, with a screen taking less than 1 week
• High success rate for drug solubilisation (95 % of compounds screened have been successfully progressed into preclinical models)
• 'Real-time' monitoring of drug dissolution and kinetic solubility, ensuring physical stability of supplied formulations for the duration of the dosing study (i.e. your formulation will not precipitate prior to administration)
• Solution stability determination, including monitoring drug precipitation upon dilution in various media that mimic the physical properties of biological fluids (such as simulated gastric fluid, FESSIF and FASSIF media)
• Formulations can either be supplied directly to your preclinical site for in vivo investigations (with supporting chemical and physical stability data to match planned study timelines) or, if you have in house capabilities for formulation manufacture, recipes and processes can be detailed.
• IP and royalty free. We will not charge you a premium to find out what excpients we are using for your API.